title: Health-related quality of life in primary antibody deficiency.
abstract: Patients with primary antibody deficiencies (PAD) are susceptible to recurrent and chronic infections and a variety of complications. This study was performed to assess quality of life (QoL) of PAD patients who were under long term treatment and regular follow-up.Thirty six adults with proved diagnosis of PAD, who had received regular intravenous immunoglobulin replacement therapy, were enrolled in this study. The QoL of selected PAD patients was measured by Medical Outcomes Study 36-item Short-Form (SF-36) Health Survey questionnaire.The patients with PAD showed significantly reduced scores in physical component in comparison with healthy age-sex matched control subjects (60.2±20.1 vs. 85.5±4.7, P<0.001). Mental component score was also significantly decreased in the patient's group (59.8±19.5 vs. 72.3±3.4, P=0.002). There was a reverse association between SF-36 scores and number of infections episodes (r=-0.73 P=0.003). The patients with long delay diagnosis showed significantly lower SF-36 scores (r=-0.62, P=0.003).The patients with PAD who were diagnosed timely and managed appropriately seem to have lower complications and better QoL. However, the patients with severe phenotypes and long delay in diagnosis showed lower QoL, even in medical management.
authors.affiliation: Research Center for Immunodeficiency, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. aghamohammadi@sina.tums.ac.ir
authors.forename: Asghar
authors.initials: A
authors.lastname: Aghamohammadi
authors.forename: Ali
authors.initials: A
authors.lastname: Montazeri
authors.forename: Hassan
authors.initials: H
authors.lastname: Abolhassani
authors.forename: Sepideh
authors.initials: S
authors.lastname: Saroukhani
authors.forename: Sarvenaz
authors.initials: S
authors.lastname: Pourjabbar
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Tavassoli
authors.forename: Behzad
authors.initials: B
authors.lastname: Darabi
authors.forename: Amir
authors.initials: A
authors.lastname: Imanzadeh
authors.forename: Nima
authors.initials: N
authors.lastname: Parvaneh
authors.forename: Nima
authors.initials: N
authors.lastname: Rezaei
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D003141:Communicable Diseases / Q000209:etiology / Q000523:psychology; D057210:Delayed Diagnosis; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007492:Iran; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011788:Quality of Life; D012008:Recurrence; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors